Sysmex Inostics, Bayer to Develop Companion Diagnostics for Cancer Therapies | GenomeWeb

NEW YORK (GenomeWeb News) — Sysmex Inostics said today that it has inked a collaboration agreement with Bayer Healthcare to develop blood-based companion diagnostics for targeted anti-cancer therapies being developed by Bayer.

Under the agreement, Sysmex Inostics, a subsidiary of Japanese in vitro diagnostics firm Sysmex, will develop blood-based diagnostic tests using its BEAMing technology, an ultra-sensitive digital PCR approach that can detect cancer cell DNA directly from blood.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.